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P ulmonary arterial hypertension (PAH) is a frequently lethal disease of relatively mysterious origins. For over 50 years it has been recognized that autoimmune phenomena are associated with certain forms of PAH, but it has never been previously demonstrated that autoimmunity, itself, may be a root cause for PAH. 1 Previous work by our group and others demonstrated that T-cell immunity is involved in PAH pathogenesis, but no study has yet sought to explain how immune dysregulation directly causes PAH. Human and rat lung PAH pathology demonstrate occlusive arterioles and immune cell aggregates comprised of macrophages, mast cells, B and T lymphocytes, and antiendothelial cell antibodies (AECAs) adherent to injured vasculature. [1] [2] [3] [4] Conditions commonly associated with PAH, such as systemic sclerosis and HIV, are associated with abnormalities in CD4 T-cell function and exhibit a similarly inflamed pulmonary vascular pathology. 1, 5 To date, it has not been clear whether inflammation surrounding the pulmonary vasculature is primarily the cause or the consequence of vascular remodeling. Given that athymic animals, which are congenitally T-cell deficient, are also particularly susceptible to the development of experimental PAH, 6 -8 we questioned whether inappropriately exuberant inflammation due to the lack of normal immune regulation could be a key predisposing factor for the development of this disease in these animals.
Injury resolution is an established function for a subset of T cells with strong regulatory activity, commonly referred to as Tregs. These cells typically express the coreceptor CD4 ϩ , the transcription factor Forkhead box protein 3 (FoxP3), and highly express the IL-2 receptor-␣ chain (ie, CD25 hi ). 9 In addition to these classical Treg populations, rats also exhibit regulatory activity in CD4 ϩ
CD25
Ϫ cells. 10 -12 Tregs participate in the regulation of immune responses following a variety of inflammatory injuries such as burns and infection. [13] [14] [15] In the absence of normal Treg activity, inflammatory injury is less readily resolved, and serious disease may develop. 16 Our group and others have demonstrated that the athymic rat develops severe PAH following vascular injury induced by monocrotaline (MCT) or VEGFR2 blockade (SU5416). 6 -8 In comparison with other PAH models, which require chronic hypoxia or a surgical pneumonectomy, T-cell immunodeficiency renders these athymic animals particularly sensitive to the development of severe PAH under normoxic conditions. The athymic rat is the result of an autosomal recessive mutation on the rnu locus (rnu/rnu) of chromosome 10 leading to T-cell deficiency, thymic aplasia, and hairlessness. 17 Following MCT or SU5416 administration, athymic rats of different genetic backgrounds develop significant RV remodeling, perivascular inflammation, and occlusive arteriolar lesions that are similar to lesion observed in severe clinical PAH. 6 -8 Prior studies utilizing athymic rats were limited by the availability of inbred animals, which precluded an evaluation of how immune dysregulation could account for the PAH diathesis. 7 In this study, we administered SU5416 to genetically inbred athymic animals and performed immune reconstitution (IR) experiments with MHCidentical cells to assess, for the first time, the role of immune regulation in the development of PAH.
Methods
A detailed Methods section can be found as an online supplement available at http://circres.ahajournals.org.
Animal Model
The experimental protocol was approved by the Veterans Affairs Palo Alto Animal Care and Use Committee. Inbred WAG (RT1u) ATHYMIC nude rats (rnu/rnu) and euthymic (rnu/ϩ) rats were utilized for these studies (Biomedical Research Models, Inc., Worcester, MA). Euthymic rats served as MHC-identical controls and as cell donors for adoptive transfer experiments. Six to 8-weekold animals were injected s.c. with a single dose of VEGFR2 antagonist SU5416 (20 mg/kg) dissolved in either DMSO or DMSO (vehicle) alone. This dose was previously determined to be effective for inducing PAH in athymic rats. 7 SU5416 was synthesized utilizing a previously described modified protocol. 18 All animals were maintained in normoxic conditions.
Immune Reconstitution
We injected 20ϫ10 6 unfractionated spleen cells obtained from euthymic male rats into athymic rats i.p. 7 days prior to SU5416 administration except for the time-course experiment in which they were injected at dϪ7, dϪ5, dϪ3, d0, d3, d5, d7, and d10, with d0 being the day of SU5416 administration. For CD4 ϩ and CD8 ϩ T cell reconstitutions 20ϫ10 6 cells were administered i.v. to athymic rats, and for CD4 ϩ CD25 hi and CD4 ϩ CD25 Ϫ cell reconstitutions, approximately 3ϫ10 6 cells were administered i.v. to athymic rats 7 days prior to SU5416 administration.
Cell Isolation and Purification

Isolation and Purification of CD4
؉ and CD8 ؉ T Cells
Spleens from inbred euthymic rats were processed and filtered through a 100-m cell strainer to obtain a single cell suspension, washed with DMEM, and then counted. CD4 ϩ T cells were purified by labeling B cells, NK cells, CD8 ϩ T cells, CD68 ϩ cells, and mast cells with the following purified antibodies (all of which were mouse IgG1 isotype): anti-CD45RA (OX-33), anti-CD161a (10/78), anti-CD8a (OX8), antimast (AR32AA4) (all BD Pharmingen, San Diego, CA), and anti-CD68 (ED-1) (AbD Serotec, Raleigh, NC). The labeled splenocytes were then incubated with rat antimouse IgG1 microbeads (Miltenyi Biotec, Bergisch Gladbach,Germany) according to the manufacturer's description. Live cells were recovered using the magnetic activated cell sorting (MACS) system with magnetic LS columns (Miltenyi Biotech). The collected negative fraction and enriched CD4 ϩ T cells were further purified with a cell sorter (FACSAria) (BD Bioscience). The average purity was Ͼ98%. The same procedure was used to isolate CD8 ϩ T cells except that instead of labeling the splenocytes with anti-CD8a prior to incubation with microbeads, they were labeled with purified anti-CD4 (OX-38) (BD Pharmingen) (average purity Ͼ98%). To obtain the CD4 ϩ T cell depleted splenocytes, we incubated the splenocyte suspension with anti-CD4 (OX-38 and OX-35) antibodies (BD Pharmingen), and then the negative fraction was isolated with microbeads as described above. ϩ CD25 Ϫ subsets, pure CD4 ϩ T cells were labeled with mouse anti-CD25-PE antibody (OX39) (BD Pharmingen), followed by incubation with anti-PE microbeads. LS columns (Miltenyi Biotec) were used with the MACS system to fractionate the 2 populations. Both cell fractions were then sorted with a fluorescent activated cell-sorting machine, FACSAria (BD Biosciences). The average purity obtained was Ͼ97.5%. Expression of FoxP3 in both of these populations was assessed by using the FoxP3 staining set buffers (eBioscience, San Diego, CA) for intracellular staining with antiFoxP3 antibody (150D) (Biolegend, San Diego, CA) according to the manufacturer's protocol. These cells were costained with antibodies to CD4 (OX-38), CD8a (OX8), CD25 (OX39), IL-10 (A5-4), CD45RA (OX-33) (all BD Pharmingen), and TCR (R73) (eBioscience). Flow cytometry was performed on a FACSCalibur (BD Biosciences), and the data were analyzed with CellQuest software (BD Biosciences).
Isolation and Purification of Tregs (CD4
Hemodynamic Measurements
The rats were anesthetized with ketamine hydrochloride (70 mg/kg) and xylazine (10 mg/kg) injected i.p. before right and left heart catheterization. Right ventricular systolic pressure (RVSP) measurements were obtained by insertion of a Micro Tip pressure transducer catheter (model SPR-671, 1.4F) (Millar Instruments, Houston, TX) through the jugular vein into the RV. Signals were recorded continuously with a TC-510 pressure control unit (Millar Instruments) coupled to a Bridge Amp (AD Instruments). Data were collected with the Powerlab4/30 data acquisition system (AD Instruments) and analyzed with Chart Pro software (AD Instruments). LV combined pressure-volume signals were recorded by insertion of a pressure-volume conductance (PV) catheter (model SPR-838, 2F) (Millar Instruments) through the carotid artery into the LV. Subsequently, a median sternotomy was performed, the pericardium was opened, and the PV catheter was introduced into the RV for measurements of RV pressure loops and pulmonary artery pressures. The PV catheter was connected to a MPVS Ultra single segment pressure volume system (Millar Instruments), and signals were recorded digitally. All data were acquired and analyzed with Chart Pro software (AD Instruments). The RV was dissected from the left ventricle (LV) and the septum (S), and each was weighed. The ratio of RV/(LVϩS) was calculated to determine the degree of RVH.
Statistical Methods
GraphPad Prism was used for statistical analysis. Differences between multiple groups were compared using 1-way analysis of variance with Bonferroni multiple-comparisons test for post hoc analyses. For datasets with nonparametric data, multiple groups were compared using the Kruskal-Wallis test, and Dunn's multiple comparisons test was used for the post test analysis. For the cytokine, histological, and Western blot analyses, unpaired t tests assuming unequal variances were utilized, with the comparisons being negative athymic control versus athymic SU and athymic SU versus athymic IR-SU groups. All data are represented as meansϮSEM, and probability value Ͻ0.05 is considered significant.
Results
IR of Athymic Rats With MHC-Identical Splenocytes Attenuates the Development of PAH When Injected Prior to SU5416 Administration
We first investigated whether inbred athymic rats exhibited more profound PAH than did euthymic rats on a WAG strain (RT1 u ) genetic background. The heterozygous rnu/ϩ euthymic rats used in this study are T cell replete and are MHC -identical to the athymic rats; a characteristic that makes them suitable as T-cell donors for the athymic rat. Right ventricle systolic pressures (RSVPs) were used to estimate PAH. SU5416-treated athymic rats developed severe PAH and right ventricular hypertrophy (RVH) in comparison with immune-replete SU-5416-treated euthymic rats, and vehicle (DMSO)-treated athymic controls. Athymic rats underwent IR with 20ϫ10 6 spleen cells 7 days prior to SU5416 administration to test whether IR with splenocytes from euthymic donors was protective against the development of PAH; IR was later confirmed by flow cytometry of peripheral blood 7 days after cell injection. IR prevented the development of PAH ( Figure 1A and 1B). PAH was associated with histologically evident pulmonary vascular remodeling, which was prevented by IR (Online Figure I) . IR led to a larger percentage of vessels being open in comparison with athymic SU5416 animals (Online Figure II) . Additionally, pressurevolume studies were performed; the RVSP and dp/dt max data from these studies supported the hypothesis that athymic SU5416 animals develop significant PAH and that the PAH is minimal in IR-athymic SU5416 animals (Online Figure III ; Online Tables I and II) .
Animals from the 3 athymic treatment groups were compared to confirm PAH by echocardiography. SU5416-treated athymic rats had significantly faster pulmonary artery acceleration times (PAAT) ( Figure 1C ), and an expanded pulmonary artery diameter (PADia) ( Figure 1D ), parameters all indicative of worsening PAH. No significant echocardiographic left ventricle differences were noted between the 3 groups (data not shown). Athymic-SU5416-treated rats underwent IR at multiple time points in relation to SU5416 administration to address whether IR protection from PAH required that the reconstituted cells be present close to the time of SU5416-mediated vascular injury; they were evaluated at d21 (Figure 2 ). IR became progressively less effective the later it was performed in relation to vascular injury. These results suggested that the protection conferred by IR involves controlling pathological events soon after the induction of vascular injury by SU5416.
Early Pulmonary Inflammation Precedes Vascular Remodeling and PAH
To assess the possibility that regulating early inflammation was responsible for the protective effect of IR, we evaluated animals d7 after SU5416 administration. Inflammation with macrophages and B cells was pronounced by d7 ( Figure 3A through  3D) . Notably, PAH was not detected by right heart catheterization or echocardiography prior to 10 days, nor was there evidence of histological evidence of vascular remodeling at this early time points. To determine whether there was evidence of systemic inflammation, we next evaluated 2 key cytokines that have been previously implicated in the development of PAH: IL-6 and TNF-␣. 19, 20 Serum was obtained from animals 7 and 21 days after SU5416 or vehicle treatment and evaluated by ELISA. PAH was associated with high-serum IL-6 and TNF-␣ levels, and was suppressed by IR ( Figure 3E and 3F).
Early Migration of Putative Tregs to Lungs in IR Animals
Given that the systemic anti-inflammatory effect that IR had on SU5416-treated animals was detected within 7 days of SU5416 administration, we next investigated whether anti-inflammatory Tregs could be detected in the lungs and blood of reconstituted animals at the time when the anti-inflammatory effect was noted. Putative Treg cells (CD4 
CD4
؉ CD25 ؉ and CD4 ؉ CD25 ؊ Subsets Are Individually Sufficient to Confer Protection Against the Development of PAH We next sought to determine which cellular subset of spleen cells used for IR was essential for the prevention of vascular injury and PAH. Although the athymic rat lacks T cells, it has a normal complement of bone-marrow-derived B cells. Although T-dependent responses such as transplant rejection and hypersensitivity reactions are impaired in these rats, the innate immune response is intact, including mast cells, NK cells, macrophages, and neutrophils. 17 Therefore, the assumption was that a missing T cell subset (absent in athymic animals) was responsible for these rats' predisposition for disease. We hypothesized that a putative CD4
ϩ Treg population was the essential T-cell subset. To rule out that CD8 T cells conferred protection against the development of PAH, we next immune-reconstituted animals with 20ϫ10 6 fractionated CD8 ϩ T cells 7 days prior to SU5416 administration and assessed the rats at d21. IR was confirmed by flow cytometry of blood at 7 days post SU5416. CD8 ϩ T cell reconstitution was nonprotective ( Figure 5A and 5B). Next, to rule out the possibility that other spleen cell populations besides CD4 ϩ T cells were conferring protection, we performed IR with CD4-depleted spleen cells. As with CD8 ϩ T cell reconstitutions, depletion of CD4 ϩ cells from the spleen cell inoculums prior to IR eliminated the ability of adoptively transferred splenocytes to block PAH and further confirmed that the protective subset of cells was CD4 ϩ (Figure 5Cand 5D ). Although we established that it is possible to uniquely generate PAH in rats under normoxic conditions that have a genetic absence of T cells, we thought that the relevance of the general model would be strengthened if an immunologically normal rat exposed to simultaneous vascular injury and CD4 depletion would also develop PAH; the immune system of animals devoid of all T cells from birth may develop in unconsidered ways. For this reason, we investigated immunologically intact euthymic rats, which are normally refractory to developing significant PAH with SU5416 therapy in normoxic conditions (Figure 1 ). Administration of a CD4-depleting monoclonal antibody, which eliminated Ͼ98% of circulating CD4 ϩ T cells prior to SU5416 administration, rendered these animals susceptible to the development of PAH (Figure 5E and 5F; Online Figure VI) . CD4-depleted animals developing PAH demonstrated increased perivascular inflammation with macrophages and B cells (Online Figure VIA and VIB) . These studies cumulatively demonstrated that a population of CD4 ϩ T cells was required to prevent PAH.
To determine whether CD4 ϩ cell subsets were differentially protective, we reconstituted athymic rats with either CD4 
IR Prevents Vascular Apoptosis
Because PAH induced by SU5416 has been attributed to the death (by apoptosis) of vascular endothelial cells, 24 we evaluated whether IR also attenuated this process. The presence of apoptotic cleaved caspase 3 ϩ CD31 ϩ cells was first noted in SU5416-treated animals 7 days after SU5416 administration ( Figure 6A ). Vascular apoptotic cells was more marked by d21 when CD31 staining is minimal, presumably due to prior endothelial cell death ( Figure 6B ). In established PAH, apoptotic cells within the vascular wall were notably CD31 Ϫ . Evidence of widespread pulmonary apoptosis was also demonstrated by increased lung cleaved caspase 3 protein levels in nonreconstituted SU5416 animals on day 7 ( Figure 6C and 6D) and day 21 ( Figure 6E and 6F) . A morphometric assessment of cleaved caspase 3 ϩ cells per vessel demonstrated relatively fewer apoptotic cells per vessel in IR-athymic rats ( Figure 6G ).
IR Results in Upregulation of Pulmonary BMPR2
To further evaluate why IR was protective against endothelial apoptosis, we next investigated BMPR2 levels in the 3 treatment groups. Given that BMPR2 is a protein characterized as vascular-protective in health and vascular-defective in PAH, 25 we tested whether IR impacted the expression of this receptor in lung tissue. Notably, all 3 groups exhibited rare BMPR2-expressing macrophages ( Figure 7A ). Global lung tissue BMPR2 levels appeared elevated in athymic IR-SU by immunochemistry ( Figure 7B ). BMPR2-expressing cells were frequently noted adjacent to CD4 ϩ cells in immunereconstituted animals ( Figure 7C ). Vascular BMPR2 expression in athymic IR-SU was notably elevated ( Figure 7D and 
7E)
. By Western blot analysis of whole lysates, BMPR2 expression was significantly increased in athymic IR-SU animals ( Figure 7F and 7G) . Thus, the protection conferred by immune reconstitution in this PAH model was strongly associated with upregulation of pulmonary BMPR2.
Discussion
The observations that T-cell-deficient athymic rats develop particularly exaggerated PAH 6 -8 and that immunodeficiency itself promotes autoimmunity 26 suggested that restoring a missing lymphocyte population could prevent PAH by limiting inflammation. Here we demonstrate for the first time that IR attenuates early inflammation following vascular injury induced with a VEGFR2 inhibitor and is protective against the subsequent development of PAH. IR of athymic animals was effective only if administered prior to SU5416 administration. This finding is consistent with the idea that in normal, immunocompetent animals, the early promotion of injury resolution by Tregs suppresses vascular inflammation and prevents PAH. In PAH development in the SU5416 model, ongoing pulmonary vascular endothelial injury and apoptosis is followed by a progressive proliferative phase of phenotyp- ically abnormal luminal cells; coupled with vascular smooth muscle hypertrophy and vasoconstriction, these pathological changes significantly increase the pulmonary vascular resistance and cause PAH. 27 This process is modeled in Figure 8 .
Inflammation in T-cell-deficient animals was notable for an accumulation of B cells and macrophages within 1 week of SU5416 administration. This finding is concordant with the fact that the loss of self-tolerance in animals missing normal Treg populations is associated with the appearance of various autoantibodies and autoimmune disease. 28, 29 With complete elimination of CD4 ϩ
CD25
hi cells, systemic autoimmunity occurs as manifested by multiorgan inflammation and autoantibody production. 16 Thus a loss of Treg-mediated self-tolerance leads not only to a loss of T-cell tolerance but also to a breakdown in B-cell tolerance. Moreover, recent data demonstrate that regulatory T cells are not restricted to regulation of the adaptive immune system but also affect the activation and function of innate immune cells including monocytes, macrophages, dendritic cells, and NK cells. 30 -33 Exuberant inflammation following vascular injury in our model can therefore be explained by a loss of self-tolerance in the absence of normal immune regulation. We determined that both CD4 ϩ
hi and CD4 ϩ CD25 Ϫ populations were sufficient for IR-mediated protection from PAH. Although CD4 ϩ CD25 hi are well described as the Tregs in mice, rats exhibit additional Treg populations in comparison with mice. In rats, coexpression of CD25 on CD4 T cells does not consistently identify all CD4 cells with regulatory function. 10 Several studies 10 -12 demonstrate regulatory activity in the CD4 ϩ
Ϫ population in rats, and this population also appears to have regulatory activity in the current model. We also present evidence that immune reconstituted CD4 ϩ
Ϫ cells may have been converted to CD4 ϩ
ϩ Tregs, as has been previously described. 23 Whether it is this conversion in the periphery or the fundamental nature of rat CD4 ϩ
Ϫ subset, these cells clearly demonstrated regulatory activity. The identification of Tregs as a crucial component of self-tolerance in other diseases has led to major advances in the understanding of how immune injury in autoimmunity and transplantation can be initiated when either insufficient numbers of Tregs or compromised Treg function occurs. 34, 35 TNF-␣ and IL-6 were elevated in the serum of rats developing PAH. TNF-␣ overexpression augments PAH. 19 IL-6, a proinflammatory and vasodepressor cytokine, has been shown to have a significant association with mortality in patients with PAH. 36 Increased serum and plexiform lesion levels of IL-6 have been found in PAH patients as well as in IL-6 Tg ϩ mice with replicative pathophysiological changes of PAH. 37 IL-6 has also recently been found to negatively regulate the TGF-␤/BMP signaling cascade. 38 The current study demonstrates that Tregs limit the systemic liberation of IL-6 and TNF-␣, a finding that lends credence to the concept that Tregs have therapeutic potential in immune-mediated inflammatory diseases characterized by high levels of these cytokines. 39, 40 Although prior studies have described TGF-␤ in relation to the vascular endothelium in PAH (eg, Zaiman et al 41 ) , the current study highlights how active TGF-␤ may also be an important cofactor expressed by Tregs to maintain self-tolerance following vascular injury. 21, 22 The proposed mechanisms by which Tregs control inflammation are numerous and involve several basic mechanisms including (1) secretion of antiinflammatory cytokines (most notably TGF-␤ and IL-10), (2) cytolysis of effector T cells, (3) metabolic disruption of effector cells (for example, by serving as an IL-2 "sink " due to high Treg surface concentrations of the IL-2 receptor protein), and (4) modification of dendritic cell function (such as through the induction of the immunosuppressive enzyme indoleamine 2,3-dioxygenase). 42 A striking accumulation of putative Tregs on day 7, including CD4 
IL-10
ϩ cells, were noted in only the IR-SU5416 lungs and were concentrated around the arterioles. Whole-lung lysate levels of pSMAD2 levels were evaluated and were increased in the IR group on d7. Over time, the diseased athymic-SU5416-treated animals developed increasing pSmad2 levels as well, indicating that increased TGF␤ signaling, in isolation, cannot explain protection from disease but should be considered in the context of which cells are involved. Tregs noted around the pulmonary arterioles in IR animals also expressed IL-10. IL-10 -mediated Treg effects have been particularly evident in antigenspecific responses and represent a normal compensatory mechanism antagonizing the inflammatory response. 43, 44 IL-10 is a potent immunomodulator that inhibits the secretion of various proinflammatory cytokines, including IL-6 and IL-8. Adenoviral expression of IL-10 protects against monocrotaline-induced pulmonary hypertension in rats. 45 Thus, IL-10 and TGF-␤ expression by Tregs offer plausible mechanisms explaining how these cells limit inflammatory injury and possibly accelerate pulmonary recovery.
IR resulted in decreased vascular apoptosis following SU5416 administration. Because endothelial apoptosis is the chief mech- Figure 6 . IR of athymic rats leads to reduced pulmonary vascular endothelial cell apoptosis. A, Immunofluorescent images of serial lung tissue sections for cleaved caspase 3 expression (arrow) at d7 after SU5416 administration. Differential interference contrast (DIC) represents small lung vessel histology, and inset shows CD31 expression in small lung vessel (nϭ8 per group). B, Immunofluorescent images of serial lung tissue sections for cleaved caspase 3 expression (arrows) at d21 after SU5416 administration. DIC image shows an almost occluded vessel and inset shows absent CD31 staining inside the lung vessel wall (nϭ8 per group). C through F, Western blot analysis from whole lung lysate for cleaved caspase 3 protein levels at d7 and d21 (nϭ8 per group). anism by which SU5416 induces PAH, 46 we sought factors associated with IR that could have protected endothelium and found that IR induced vascular BMPR2 expression. BMPR2 mutations are strongly associated with familial PAH, 47 and decreased pulmonary vascular BMPR2 expression is associated with idiopathic PAH. 48 In experimental models, hypoxiainduced PAH is associated with down-regulation of pulmonary vascular BMPR2, and genetic ablation of pulmonary vascular BMPR2 favors PAH development. 25 In the current study, BMPR2-expressing cells in athymic control and athymic SU5416 groups were confined to rare cells that we were not able to characterize, except that they were sometimes CD68 ϩ macrophages. By contrast, IR athymic SU5416 animals exhibited large numbers of BMPR2-expressing cells often adjacent to CD4ϩ cells. Additionally, we demonstrate increased BMPR2-expressing pulmonary vascular cells only in the IR group. The mechanism by which IR could result in such BMPR2 upregulation is not known, nor is it understood whether there is a direct causal relationship between immune competency and BMPR2 expression. Of interest, a close (physical) association between BMPR2 expressing cells and T cells was recently observed in idiopathic PAH, 49 and future studies will investigate by what mechanism T cells might directly induce endothelial BMPR2.
Treg IR studies in rats are costly, are time consuming, and have limited reagents available in comparison with mice, but rat models benefit from more robust disease that more closely resembles human PAH pathology. 50 Whereas pulmonary inflammation in PAH is a well-established phenomenon, 3, 5 it has been unclear whether the inflammation is itself pathogenic or is a secondary immune response to preexisting pulmonary vascular disease. The current study strongly implicates inflammation associated with CD4 immunodeficiency as a primary predisposing factor to experimental PAH development. The clinical relevance of this finding is that certain PAH-associated conditions are characterized by abnormalities in CD4 ϩ T cell number and function. Examples of this association include HIV infection and autoimmune diseases such as systemic sclerosis, systemic lupus erythematosus, polymyositis, Hashimoto's thyroiditis, Sjögren's Syndrome, and the antiphospholipid antibody syndrome. [51] [52] [53] [54] [55] [56] [57] The clinical relevance of this issue is that these CD4 ϩ T cell irregularities may render patients susceptible to exaggerated vascular inflammation and subsequent vascular remodeling following vascular injury. By distinction, idiopathic PAH has been characterized by increased Tregs in peripheral blood accompanied by a 4-fold elevation of lung CD8 ϩ cells. 58, 59 Therefore, in the case of idiopathic PAH, if immune dysregulation contributes to the lung inflammation observed in this condition, current evidence does not link pulmonary injury to abnormal CD4 ϩ T cell populations detectable in the periphery. Correcting immune dysregulation with Treg therapy 60 is an exciting application in development, which could prove useful for some PAH conditions. 60 Greater recognition that PAH patients have a condition that may begin with impaired resolution of vascular injury could have a significant impact on how this condition is both understood and treated.
What New Information Does This Article Contribute?
• Correcting immune deficiency prevents experimental PAH.
• The protective effect of IR was localized to Treg populations that prevented the early accumulation of macrophages and B cells, limited pulmonary endothelial apoptosis, and upregulated vascular bone morphogenetic protein receptor-II (BMPR2) expression.
Clinical conditions commonly associated with PAH, such as systemic sclerosis and HIV infection, are characterized by abnormal CD4 T lymphocyte function and number, T-cell abnormalities that are likely responsible for some of the dysregulated immunity observed in these conditions. Preclinical studies have shown that T-cell-deficient rats develop lung inflammation and exaggerated PAH following vascular injury.
The purpose of the current study was to determine whether restoring T lymphocyte function and number abrogates exuberant inflammatory responses and prevents PAH. We found that lung injury resolution, in the presence of Tregs, is associated with significantly less inflammation and endothelial apoptosis. Inflammation was not merely a consequence of PAH because inflammation and apoptotic cell death occurred prior to the development of vascular remodeling and elevated pulmonary artery pressures. Unexpectedly, the restoration of T cells also led to upregulated vascular BMPR2 in protected rats. This finding is of interest because BMPR2 mutations have been implicated as a cause of familial PAH, and decreased pulmonary vascular BMPR2 expression has been observed in other forms of PAH. These findings suggest that anti-inflammatory Tregs, in association with inducible BMPR2, provide innate protection against PAH following pulmonary vascular injury.
